|
著者: Rie Suematsu, Akihide Ohta, Emi Matsuura, Hiroki Takahashi, Takao Fujii, Takahiko Horiuchi, Seiji Minota, Yoshiaki Ishigatsubo, Toshiyuki Ota, Shuji Takei, Sachiko Soejima, Hisako Inoue, Syuichi Koarada, Yoshifumi Tada, Kohei Nagasawa
雑誌名: Mod Rheumatol. 2012 Sep;22(5):712-9. doi: 10.1007/s10165-011-0569-6. Epub 2011 Dec 9.
Abstract/Text
OBJECTIVE: The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. METHOD: Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. RESULTS: Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. CONCLUSION: Tocilizumab may be a promising biologic agent in refractory ASD.
PMID 22160845 Mod Rheumatol. 2012 Sep;22(5):712-9. doi: 10.1007/s10165-011-0569-6. Epub 2011 Dec 9.
|